Increasing evidence indicates that caspase activation and apoptosis are associated with a variety of neurodegenerative disorders, including Alzheimer's disease. We reported that anesthetic isoflurane can induce apoptosis, alter processing of the amyloid precursor protein (APP), and increase amyloid-␤ protein (A␤) generation. However, the mechanism by which isoflurane induces apoptosis is primarily unknown. We therefore set out to assess effects of extracellular calcium concentration on isoflurane-induced caspase-3 activation in H4 human neuroglioma cells stably transfected to express human full-length APP (H4-APP cells). In addition, we tested effects of RNA interference (RNAi) silencing of IP 3 receptor, NMDA receptor, and endoplasmic reticulum (ER) calcium pump, sacro-/ER calcium ATPase (SERCA1). Finally, we examined the effects of the NMDA receptor partial antagonist, memantine, in H4-APP cells and brain tissue of naive mice. EDTA (10 mM), BAPTA (10 M), and RNAi silencing of IP 3 receptor, NMDA receptor, or SERCA1 attenuated capase-3 activation. Memantine (4 M) inhibited isoflurane-induced elevations in cytosolic calcium levels and attenuated isoflurane-induced caspase-3 activation, apoptosis, and cell viability. Memantine (20 mg/kg, i.p.) reduced isoflurane-induced caspase-3 activation in brain tissue of naive mice. These results suggest that disruption of calcium homeostasis underlies isoflurane-induced caspase activation and apoptosis. We also show for the first time that the NMDA receptor partial antagonist, memantine, can prevent isoflurane-induced caspase-3 activation and apoptosis in vivo and in vitro. These findings, indicating that isoflurane-induced caspase activation and apoptosis are dependent on cytosolic calcium levels, should facilitate the provision of safer anesthesia care, especially for Alzheimer's disease and elderly patients.
Introduction
Cerebral deposition of amyloid ␤-protein (A␤), derived from the amyloid precursor protein (APP), is a major pathological hallmark of Alzheimer's disease (AD) (for review, see Selkoe, 2001; Tanzi and Bertram, 2005) . Increasing evidence suggests a role for caspase activation and apoptosis in AD neuropathogenesis (Gervais et al., 1999; LeBlanc et al., 1999; Lu et al., 2000; Eckert et al., 2003; Gastard et al., 2003; Zhao et al., 2003; Hitomi et al., 2004; Takuma et al., 2004) .
Several studies showed the potential association of previous general anesthesia/surgery and risk of AD (Bohnen et al., 1994a,b; Muravchick and Smith, 1995) . A previous study suggested that age of onset of AD was inversely related to anesthesia exposure before 50 years of age (Bohnen et al., 1994b) . A recent study also reported that patients undergoing coronary artery bypass graft surgery under general anesthesia were at increased risk for AD compared with those having percutaneous transluminal coronary angioplasty under local anesthesia (Lee et al., 2005) . Isoflurane, one of the most commonly used inhalation anesthetics, has been reported to enhance aggregation and cytotoxicity of A␤ (Eckenhoff et al., 2004) and induce caspase activation and apoptosis (Matsuoka et al., 2001; Jevtovic-Todorovic et al., 2003; Kvolik et al., 2005; Loop et al., 2005; Wei et al., 2005; Yon et al., 2005) . Our recent studies have shown that a clinically relevant isoflurane treatment causes caspase-3 activation and apoptosis, decreases cell viability, affects APP processing, and increases A␤ generation in human neuroglioma cells stably transfected to express human APP (H4-APP cells) (Xie et al., 2006a (Xie et al., ,b, 2007 . Moreover, isoflurane has been suggested to induce a vicious cycle of apoptosis and A␤ accumulation (Xie et al., 2007) .
The mechanism by which isoflurane induces caspase activation and apoptosis remains unclear. Wei et al. (2005 Wei et al. ( , 2008 reported that dantrolene, an endoplasmic reticulum (ER) ryanodine receptor antagonist, and inositol 1,4,5-trisphosphate (IP 3 ) receptor knock-out can inhibit isoflurane-induced apoptosis, suggesting that abnormal calcium release from ER after isoflurane treatment may cause apoptosis (Wei et al., 2005 (Wei et al., , 2008 . Here, we used a variety of treatments in vitro and in vivo to alter calcium homeostasis and assessed the effects of these treatments on isoflurane-induced caspase-3 activation in H4-APP cells. The IP 3 receptor, located in the ER membrane, regulates release of calcium from the ER to the cytoplasm (Berridge, 1993) . Activation of IP 3 receptors causes elevated cytosolic calcium levels, leading to cell death (Hanson et al., 2004; Lindholm et al., 2006) . A recent study by Zhang et al. (2006) showed that the endoplasmic reticulum calcium pump, sacro-/ER calcium ATPase (SERCA1), is required for calcium release-activated channel activity, and RNA interference (RNAi) knockdown of SERCA1 inhibits calcium release-activated channel activity. We therefore assessed effects of RNAi silencing of IP 3 receptor, NMDA receptor, and SERCA1 on isoflurane-induced caspase-3 activation in H4-APP cells. Memantine is a relatively new FDA-approved drug for the treatment of AD, which acts as an uncompetitive (partial) antagonist of the NMDA receptor (for review, see Lipton, 2006) . We assessed the effects of memantine on isoflurane-induced caspase-3 activation both in H4-APP cells and in naive mice.
Materials and Methods
Cell lines. We used naive H4 human neuroglioma cells stably transfected to express full-length APP (FL-APP; H4-APP cells) in the studies. The cells were cultured in DMEM (high glucose) containing 9% heatinactivated fetal calf serum, 100 U/ml penicillin, 100 g/ml streptomycin, 2 mM L-glutamine, and 200 g/ml G418.
Cell treatment. Twenty-one percent O 2 , 5% CO 2 , and 2% isoflurane were delivered from an anesthesia machine to a sealed plastic box in a 37°C elsius incubator containing six-well plates seeded with one million cells in 1.5 ml of cell culture media as described in our previous studies (Xie et al., 2006a (Xie et al., ,b, 2007 . Datex infrared gas analyzer (Puritan-Bennett, Tewksbury, MA) was used to continuously monitor the delivered CO 2 , O 2 , and isoflurane concentrations. We treated the cells with 2% isoflurane for 6 h, during which time the cells were incubated in serum-free media. In the interaction studies, the cells were treated with memantine (4 M) 1 h before the treatment of 2% isoflurane. Low-calcium condition was created by using a calcium-free cell culture media (Invitrogen, Carlsbad, CA) and by adding EDTA (10 mM; Sigma-Aldrich, St. Louis, MO), a chelating compound (Rekasi et al., 2005) , or BAPTA (10 M; SigmaAldrich), an intracellular calcium chelator, to the media. To avoid offtarget effects of RNAi, we used two sets of small interference RNAs (siRNAs) aimed at knockdown of NMDA receptor (NR)1 (first set, 3ЈGCCGGGAUCUUCCUGAUUUUU, 5Ј-PAAAUCAGGAAGAUC-CCGGCUU; second set, 3ЈGGAGCACGCUGGACUCGUUUU, 5ЈPAACGAGUCCAGCGUGCUCCUU), IP 3 receptor (first set, 3ЈGCAAUCACAUGUGGAAAUUUU, 5Ј-AAUUUCCACAUGU-GAUUGCUU; second set, 3ЈUGGAAAGUCUGACCGAAUAUU, 5ЈPUAUUCGGUCAGACUUUCCAUU), and SERCA (first set, 3Ј UCG-CACAAGUCCAAGAUUGUU, 5Ј-CAAUCUUGGACUUGUGC-GAUU; second set, 3ЈGGCCAAAGGUGUCUAUGAGUU, 5Ј-PCUCAUAGACACCUUUGGCCUU). These siRNAs and control siRNAs (3ЈUAGCGACUAAACACAUCAAUU) were obtained from Dharmacon (Lafayette, CO). siRNAs were transfected into cells by using electroporation (Amaxa Biosystems, Gaithersburg, MD) as described by Xie et al. (2005b) . Briefly, we mixed 1 million cells, 100 l of AMAXA electroporation transfection solution, and 10 l of 20 M siRNA together and then used the C-9 program in an AMAXA electroporation device for cell transfection. The transfected cells were then placed in one of the six-well plates containing 1.5 ml of cell culture media. The pretreated cells were then exposed to the isoflurane treatment.
Cell lysis and protein amount quantification. Cell pellets were detergent-extracted on ice using immunoprecipitation buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.5% Nonidet P-40) plus protease inhibitors (1 g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin A). The lysates were collected, centrifuged at 12,000 rpm for 10 min, and quantified for total proteins by a BCA protein assay kit (Pierce Technology Corporation, Iselin, NJ).
Cytosolic calcium measurement. Cytosolic calcium levels were determined as described by Wei et al. (2008) . Specifically, H4-APP cells were loaded with Fura-2 (Invitrogen), perfused with Tyrode buffer, and [Ca 2ϩ ] i transients were recorded as changes in Fura-2 ratio (340/380 nm) using a spectrofluoroscope system (Ionoptix, Milton, MA). The cells were exposed to isoflurane (1 mM or 3.5%) with or without pretreatment with memantine (4 M).
Mice treatment. The animal protocol was approved by the Massachusetts General Hospital Standing Committee on Animals. Sixteen female C57BL/6 mice (5-6 months of age) (The Jackson Laboratory, Bar Harbor, ME) were randomly assigned to an anesthesia or control group. Mice randomized to the anesthesia group (n ϭ 8) received three sessions of 1.4% isoflurane in 100% oxygen for 2 h in an anesthetizing chamber. The mice were placed in 100% oxygen without isoflurane in the chamber for 10 min between each session. This isoflurane treatment allows the mice to have sufficient exposure to isoflurane while avoiding excessive accumulation of CO 2 . The control mice (n ϭ 8) received 100% oxygen at an identical flow rate for 6 h and 20 min in an identical chamber. The mice breathed spontaneously, and anesthetic and oxygen concentrations were measured continuously (Datex, Puritan-Bennett; Ohmeda PPD, Madison, WI). Rectal temperature was measured intermittently, and the temperature of the anesthetizing chamber was controlled to maintain rectal temperature of the animals at 37 Ϯ 0.5°C. Mean arterial blood pressure was measured noninvasively using a tail cuff (CODA2 system; Kent Scientific Corporation, Torrington, CT) in the anesthetized mice. This treatment of isoflurane did not significantly affect the blood pressure or blood gas of the mice (data not shown). Mice were killed by decapitation at the end of the experiments, the brain was removed rapidly, and the prefrontal cortex was dissected out and frozen in liquid nitrogen for subsequent processing for the determination of caspase-3 activation. For interaction studies, half of the anesthetized mice and half of the control mice received memantine (20 mg/kg) by intraperitoneal injection 1 h before the isoflurane treatment (Chen et al., 1998) .
Brain tissue lysis and protein amount quantification. The harvested brain tissues were homogenized on ice using immunoprecipitation buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM EDTA, 0.5% Nonidet P-40) plus protease inhibitors (1 g/ml aprotinin, 1 g/ml leupeptin, 1 g/ml pepstatin A). The lysates were collected, centrifuged at 12,000 rpm for 10 min, and quantified for total proteins by a BCA protein assay kit (Pierce Technology Corporation).
Western blot analysis. The harvested cells and brain tissues were subjected to Western blots as described by Xie et al. (2005a) . A caspase-3 antibody (1:1000 dilution; Cell Signaling Technology, Beverly, MA) was used to recognize caspase-3 fragment (17-20 kDa) resulting from cleavage at asparate position 175 and FL-caspase-3 (35-40 kDa). Caspase-3 cleavage (activation) is based on the ratio of caspase-3 fragment to FLcaspase-3. Antibody anti-␤-actin was used to visualize ␤-actin (42 kDa). Antibodies for IP 3 receptor (1:1000; Millipore Bioscience Research Reagents, Temecula, CA), NR1 (1:1000; PhosphoSolutions, Aurora, CO), and SERCA1 (1:1000; Abcam, Cambridge, MA) were used to recognize IP 3 receptor (250 kDa), NR1 (120 kDa), and SERCA1 (110 kDa). The quantitation of Western blots was performed as described by Xie et al. (2005a) . Briefly, the intensity of signals was analyzed by using a Bio-Rad (Hercules, CA) image program (Quantity One) and an NIH Image version 1.37v. We quantified the Western blots using two steps. First, we used levels of ␤-actin to normalize (e.g., determining the ratio of FL-caspase-3 amount to ␤-actin amount) levels of proteins to control for loading differences in total protein amounts. Second, we presented changes in levels of proteins in the mice or cells treated with isoflurane as the percentage of those in the mice or cells treated with controls.
Cell viability assay. 3-(4, 5-Dimethylthiazol-2-yl)2,5diphenyltetrazolium bromide (MTT, Thiazolyl blue) is a water soluble tetrazolium salt. Dissolved MTT is converted to the insoluble purple formazan by cleavage of the tetrazolium ring by dehydrogenase enzymes. Active mitochondrion dehydrogenase (only in viable cells) will cause this conversion. We used a MTT assay kit (Sigma-Aldrich) to measure cell viability. The absorbency was measured with a spectrophotometer at a wavelength of 570 nm with background subtraction at 630 nm. Cell viability reduction suggests cell death.
Cell apoptosis assay. Cell apoptosis was assessed by a cell death detection ELISA kit (Roche, Palo Alto, CA), which assays cytoplasmic histoneassociated DNA fragmentation associated with cellular apoptosis.
Statistics. Changes in caspase-3 activation were presented as a percentage of those of the control group. One hundred percent caspase-3 activation refers to control levels for purposes of comparison with experimental conditions. Data were expressed as mean Ϯ SD. The number of samples varied from 3 to 10, and the samples were normally distributed. We used two-tailed t test to compare the difference between the experimental groups and control groups. p values Ͻ0.05 (* or # ) and 0.01 (** or ## ) were considered statistically significant.
Results
Memantine attenuates isofluraneinduced caspase-3 activation, cell viability reduction, and apoptosis in H4-APP cells We reported previously that isoflurane can induce caspase-3 cleavage (activation) in H4-APP cells (Xie et al., 2006a (Xie et al., ,b, 2007 . The underlying molecular mechanisms, however, remain primarily to be determined. Recent studies have shown that elevated levels of cytosolic calcium released from the ER may be at least partially responsible for isoflurane-induced caspase-3 activation and apoptosis (Wei et al., 2005 (Wei et al., , 2008 . Memantine, a newly FDA approved drug for AD (Lipton, 2006) , is a partial antagonist for the NMDA receptor, which can reduce influx of extracellular calcium. We therefore set out to assess whether memantine can attenuate isoflurane-induced caspase activation in H4-APP cells. Because caspase activation alone cannot report cell death (McLaughlin et al., 2003) , we also monitored effects of isoflurane and memantine on cell viability and apoptosis in H4-APP cells.
Immunoblotting for caspase-3 revealed increases in caspase-3 fragment and decreases in FL-caspase-3 in H4-APP cells treated with 2% isoflurane compared with those cells in control conditions (Fig. 1 A) . Treatment with memantine plus isoflurane led to a visible decrease in caspase-3 activation compared with isoflurane treatment alone ( Fig. 1 A) . Memantine treatment alone did not induce caspase-3 activation compared with control conditions (Fig. 1 A) .
Quantification of the results showed that isoflurane treatment led to a 184% increase in caspase-3 activation compared with control conditions (Fig. 1 B) ( p ϭ 0.015). Memantine plus isoflurane yielded a significant reduction in isoflurane-induced caspase-3 activation ( Fig. 1 B) : 101 versus 184% ( p ϭ 0.013). These results indicate that a clinically relevant concentration (2%) of isoflurane can induce apoptosis in H4-APP cells, and a clinically relevant concentration of memantine can attenuate isoflurane-induced caspase-3 activation (apoptosis). Memantine alone did not increase caspase-3 activation compared with control conditions (Fig. 1 B) .
MTT cell viability and cell apoptosis studies showed that isoflurane treatment led to a 26% reduction in cell viability ( Treatment with 4 M memantine alone does not cause caspase-3 activation (lanes 2 and 3) compared with control condition (lane 1). However, treatment with isoflurane plus memantine (lanes 5 and 6) causes a lesser degree of caspase-3 activation compared with isoflurane treatment alone (lane 4). There is no significant difference in amounts of ␤-actin in all of the above treatments. B, The 2% isoflurane treatment (black) increases caspase-3 activation compared with control conditions (white), normalized to ␤-actin levels. Memantine treatment alone (gray) does not induce caspase-3 activation compared with control condition (white); however, memantine treatment (lined) attenuates the isoflurane-induced (black) caspase-3 activation, normalized to ␤-actin levels. C, Isoflurane treatment (2%) (black) decreases cell viability compared with control conditions (white). Memantine treatment alone (gray) does not affect cell viability compared with control conditions (white); however, memantine treatment (lined) attenuates the isoflurane-induced reduction in cell viability (black). D, Isoflurane treatment (2%) (black) induces apoptosis compared with control conditions (white). Memantine treatment alone (gray) does not induce apoptosis compared with control conditions (white); however, memantine treatment (lined) attenuates isoflurane-induced apoptosis (black). E, H4-APP cells contain NR1. Western blot analysis illustrates that anti-NR1 antibody (lanes 1-3) detects NR1 in H4-APP cells, whereas NR1 peptide (lanes 4 -6) prevents anti-NR1 antibody from detecting NR1 in H4-APP cells. These results suggest that there is NR1 in H4-APP cells. Data are means Ϯ SD (n ϭ 3-9 for each experimental group). A t test is used to compare the difference between control condition and the isoflurane or memantine treatment. The asterisk indicates the difference between isoflurane and control condition on caspase-3 activation (*p ϭ 0.015), cell viability (*p ϭ 0.001), and apoptosis (*p ϭ 0.001); the difference between saline and memantine on isoflurane-induced caspase-3 activation ( # p ϭ 0.013), cell viability ( # p ϭ 0.037), and apoptosis ( # p ϭ 0.001) is indicated.
1C) ( p ϭ 0.001) and a 137% increase in cell apoptosis (Fig. 1 D) ( p ϭ 0.001) in H4-APP cells, compared with control conditions, respectively. Memantine treatment significantly attenuated the isoflurane-induced reduction in cell viability (Fig. 1C) , 74 versus 95% ( p ϭ 0.037), and isoflurane-induced apoptosis (Fig. 1 D) , 137 versus 99% ( p ϭ 0.001). Meanwhile, memantine treatment alone had no effects on either cell viability or apoptosis compared with control conditions in H4-APP cells. These results suggest that isoflurane can induce caspase-3 activation, cell viability reduction, and apoptosis in H4-APP cells, and memamtine can attenuate isoflurane-induced apoptotic cell damage, conceivably via antagonism of NMDA receptors. Furthermore, immunoblotting for NR1 specifically revealed that there are NMDA receptors in H4-APP cells (Fig. 1 E) , the cell lines in which memantine was able to attenuate effects of isoflurane on caspase-3 activation, cell viability reduction, and apoptosis. These findings further suggest that memantine may act on NMDA receptors to inhibit isoflurane-induced apoptotic cell damage.
Memantine inhibits isoflurane-induced elevation in cytosolic calcium levels in H4-APP cells
Given that excessive cytosolic calcium levels can trigger caspase activation and apoptosis (for review, see Mattson, 2007) , and isoflurane may induce apoptosis via elevation of cytosolic calcium levels (Wei et al., 2005 (Wei et al., , 2008 , we next asked whether memantine can inhibit the isoflurane-induced elevation in cytosolic calcium levels in H4-APP cells. We found that the isoflurane (1 mM or 3.5%) treatment can elevate cytosolic calcium levels in H4-APP cells (Fig. 2 A) . In contrast, in the H4-APP cells pretreated with memantine (4 M), isoflurane failed to increase cytosolic calcium levels (Fig. 2 B) . These results suggest that memantine may inhibit the isoflurane-induced elevation in cytosolic calcium to attenuate isoflurane-induced caspase activation and apoptosis.
Memantine attenuates isoflurane-induced caspase-3 activation in mouse brain
We next set out to assess the effects of memantine on isofluraneinduced caspase-3 activation in vivo in naive mice. After establishing that treatment with 1.4% isoflurane for 2 h did not significantly affect blood pressure and venous blood gas (data not shown), we exposed the mice to 1.4% isoflurane treatment for three 2 h sessions with 10 min between each session. This treatment enabled the mice to have enough isoflurane exposure yet avoid severe CO 2 accumulation, because the mice reach a fully awake status between each session.
The three sessions of 1.4% isoflurane for 2 h induced caspase-3 activation in the mouse brain compared with the control conditions (Fig. 3A) . Treatment with memantine (20 mg/kg, intraperitoneal route) plus isoflurane (three sessions of the treatment with 1.4% isoflurane for 2 h) led to a visible decrease in caspase-3 activation compared with isoflurane treatment alone (Fig. 3A) . Treatment with memantine (20 mg/kg, intraperitoneal route) alone did not induce caspase-3 activation compared with the control condition (Fig. 3A) .
Quantification of these results showed that the isoflurane treatment led to 177% increase in caspase-3 activation compared with control condition (Fig. 3B) ( p ϭ 0.034). Treatment with memantine plus isoflurane significantly reduced caspase-3 activation compared with isoflurane treatment alone (Fig. 3B) ( p ϭ 0.020; 177 vs 97%). Memantine treatment alone did not induce caspase-3 activation compared with the control condition (Fig.   3B ). Collectively, all of these findings showed that the NMDA receptor partial antagonist, memantine, can attenuate isofluraneinduced apoptosis both in vivo and in vitro.
RNAi knockdown of NR1 reduces isoflurane-induced caspase-3 activation
Given that memantine can attenuate isoflurane-induced apoptosis, we next asked whether reductions in protein levels of NMDA receptors could also decrease isoflurane-induced apoptosis. We therefore assessed the effects of RNAi-mediated knockdown of NR1 on isoflurane-induced caspase-3 activation in H4-APP cells. RNAi silencing of NR1 significantly reduced NR1 levels (Fig.  4 A, B) , 100 versus 62% ( p ϭ 0.0439). Treatment with 2% isoflurane for 6 h induced caspase-3 activation (Fig. 4C , lanes 5 and 6, D, black) ( p ϭ 0.041). RNAi knockdown of NR1 (Fig. 4C, lanes 7  and 8, D, lined) attenuated isoflurane-induced caspase-3 activation in H4-APP cells, 168 versus 93% ( p ϭ 0.037). We repeated these experiments with different NR1 siRNAs and observed sim- Figure 2 . Isoflurane-induced elevation of cytosolic calcium levels can be inhibited by memantine in H4-APP cells. A, Isoflurane elevates cytosolic calcium levels in H4-APP cells. Isoflurane (1 mM; or 3.5%) was given to H4-APP cells at time 0. Cytosolic calcium levels were elevated after isoflurane treatment in H4-APP cells. B, Memantine inhibits isoflurane-induced elevation of cytosolic calcium levels in H4-APP cells. H4-APP cells were pretreated with 4 M memantine for 5 min and then exposed to 1 mM (or 3.5%) isoflurane at time 0. Note that cytosolic calcium levels were not elevated by isoflurane in the memantine-pretreated H4-APP cells. These are representative tracings of two independent experiments. ilar effects: RNAi knockdown of NR1 attenuated isofluraneinduced caspase-3 activation in H4-APP cells (data not shown). These findings suggest that the effects of RNAi knockdown of NR1 on isoflurane-induced caspase-3 activation are not likely to be caused by off-target effects of RNAi silencing of NR1. Collectively, these findings suggest that NR1 plays a role in isofluraneinduced caspase activation and apoptosis.
Reduced extracellular and intracellular calcium levels attenuate isoflurane-induced caspase-3 activation Excitotoxic neuronal cell damage can be exacerbated by hyperactivation of NMDA receptors, which results in excessive calcium influx and subsequent free radical formation (for review, see Lipton, 2006) . Isoflurane has been reported to induce apoptosis by elevating cytosolic calcium levels (Wei et al., 2005) . Given that memantine and RNAi knockdown of NR1 attenuated isofluraneinduced apoptosis, we next addressed whether this involves partial inhibition of calcium influx by exposing H4-APP cells to low-calcium levels and/or treating with the chelator EDTA. Treatment with isoflurane plus low calcium led to a visible reduction in caspase-3 activation compared with treatment with isoflurane under normal calcium conditions (Fig. 5A) . Treatment with isoflurane plus low calcium plus EDTA led to even less caspase-3 activation compared with either isoflurane alone or isoflurane plus low calcium (Fig. 5A) . Quantitation of these results revealed that treatment with isoflurane plus low calcium (Fig. 5B, gray) led to a 19% reduction ( p ϭ 0.046) in caspase-3 activation compared with isoflurane plus normal calcium condition (Fig. 5B, white) . Treatment with isoflurane plus low calcium and EDTA (Fig. 5B,  black) led to an even greater (68%; p ϭ 0.015) reduction in caspase-3 activation compared with the treatment with isoflurane plus normal calcium (Fig. 5B, white) .
To further confirm that isoflurane-induced caspase-3 activation is associated with cytosolic calcium levels, we assessed effects of BAPTA, an intracellular calcium chelator, on isofluraneinduced caspase-3 activation in H4-APP cells. Treatment with 2% isoflurane for 6 h induced caspase-3 activation (Fig. 5C , lanes 5 and 6, D, black) ( p ϭ 0.0102). BAPTA (Fig. 5C , lanes 7 and 8, D, lined) attenuated isoflurane-induced caspase-3 activation in H4-APP cells, 185 versus 154% ( p ϭ 0.045). Collectively, these results suggest that the isoflurane-induced apoptosis is dependent on both external and cytosolic calcium concentration.
RNAi silencing of IP 3 receptor and SERCA1 attenuate isoflurane-induced caspase-3 activation
We next asked whether isoflurane-induced apoptosis is dependent on internal calcium released from ER via the IP 3 receptor and SERCA1. We first established RNAi knockdown of IP 3 receptor in H4-APP cells using siRNA treatment (Fig. 6 A) . Treatment with isoflurane plus control siRNA led to a visible increase in caspase-3 activation compared with the treatment with control condition plus control siRNA (Fig. 6 A) . RNAi silencing of IP 3 receptor alone did not induce caspase-3 activation compared with the treatment with control condition plus control siRNA (Fig. 6 A) . However, treatment with isoflurane plus IP 3 receptor siRNA attenuated caspase-3 activation compared with the treatment with isoflurane plus control siRNA (Fig. 6 A) . Quantification of these data showed that RNAi knockdown of IP 3 receptor led to a 33% reduction in protein levels of IP 3 receptor compared with control siRNA treatment (Fig. 6 B) ( p ϭ 0.026). Treatment with IP 3 receptor siRNA alone had no effect on caspase-3 activation (Fig. 6C ). Although treatment with isoflurane plus control siRNA led to a 292% increase ( p ϭ 0.001) in caspase-3 activation compared with the control, treatment with isoflurane plus IP 3 receptor siRNA (Fig. 6C) led to less caspase-3 activation than did treatment with isoflurane plus control siRNA, 222 versus 292% ( p ϭ 0.035). These results suggest that knockdown of IP 3 receptor via RNAi can attenuate isoflurane-induced caspase-3 activation (apoptosis). Next, we assessed the effects of RNAi-mediated knockdown of SERCA1 on isoflurane-induced caspase-3 activation in H4-APP cells. RNAi-mediated knockdown of SERCA1 reduced SERCA1 levels by 33% ( p ϭ 0.021) (Fig. 7 A, B) . RNAi knockdown of SERCA1 (Fig. 7C,D) inhibited isoflurane-induced caspase-3 activation in H4-APP cells, 194% (control siRNA) versus 117% (SERCA1 siRNA) ( p ϭ 0.012). To avoid off-target effects of RNAi knockdown of IP 3 receptor and SERCA, we repeated these experiment with different IP 3 receptor or SERCA siRNAs and observed similar effects: RNAi knockdown of IP 3 . However, treatment with isoflurane plus memantine (lanes 4) causes a reduction in caspase-3 activation compared with isoflurane treatment alone (lane 3). There is no significant difference in the amounts of ␤-actin in all of the treatments. The Western blot, which shows the caspase-3 fragment (17 kDa) only, is the same Western blot with longer exposure time during the film development. B, Isoflurane treatment (black) increases caspase-3 activation compared with control conditions (white), normalized to ␤-actin levels, in naive mice. Memantine treatment alone (gray) does not induce caspase-3 activation compared with control condition (white); however, memantine treatment (lined) attenuates the isoflurane-induced (black) caspase-3 activation, normalized to ␤-actin levels. Data are means Ϯ SD (n ϭ 4 for each experimental group). A t test is used to compare the difference between control condition and the isoflurane or memantine treatment. *p ϭ 0.034, difference between isoflurane and control condition on caspase-3 activation; # p ϭ 0.020, difference between saline and memantine on isoflurane-induced caspase-3 activation. receptor and SERCA attenuated isoflurane-induced caspase-3 activation in H4-APP cells (data not shown). Collectively, these findings suggest that isoflurane induction of caspase activation and apoptosis is dependent on calcium release from the ER.
Discussion
The commonly used inhalation anesthetic isoflurane has been shown previously to induce caspase activation, apoptosis, and enhanced A␤ generation in cultured cells and brain slices (Matsuoka et al., 2001; Jevtovic-Todorovic et al., 2003; Eckenhoff et al., 2004; Loop et al., 2005; Wei et al., 2005; Wise-Faberowski et al., 2005; Xie et al., 2006a Xie et al., ,b, 2007 . However, the mechanism by which isoflurane induces caspase activation and apoptosis is not clear. It has been suggested that isoflurane may trigger abnormal calcium release from ER to induce caspase activation and apoptosis (Wei et al., 2005 (Wei et al., , 2008 . We show that reductions in extracellular calcium concentration can attenuate isoflurane-induced caspase-3 activation in H4-APP cells, as does RNAi silencing of the IP 3 receptor, NR1, and SERCA1. Normal NMDA receptor activity is necessary for induction of long-term potentiation (LTP), a form of synaptic plasticity associated with learning and memory. Hyperactivity of the NMDA receptor, after certain pathological conditions, can engender excessive neuronal calcium influx leading to cellular damage [e.g., apoptosis (for review, see Lipton, 2006) ]. Here, we have shown that the partial NMDA receptor antagonist memantine can attenuate isoflurane-induced caspase-3 activation in H4-APP cells. Given that caspase-3 activation alone may not suggest cell damage but rather may be essential for neuroprotection in preconditioning (McLaughlin et al., 2003) , we also measured effects of isoflurane and memantine on cell viability and apoptosis. We found that memantine can attenuate isoflurane-induced apoptosis and cell viability reduction, which suggests that memantine can inhibit isoflurane-induced apoptotic cell damage. Memantine also attenuated isoflurane-induced elevated cytosolic calcium levels in H4-APP cells and isoflurane-induced caspase-3 activation in the mouse brain in vivo. Collectively, these findings indicate that isoflurane-induced apoptotic cell damage is driven by calcium dyshomeostasis and can be pharmacologically modulated by memantine.
Isoflurane has been reported to affect synapse function by acting on the ion channels, including sodium, potassium, and calcium channels, associated with neurotransmitter receptors such as nicotinic, serotonin type 3, GABA A , glycine, and glutamate receptors (Franks and Lieb, 1998; Mennerick et al., 1998; Narahashi et al., 1998 ) (for review, see Campagna et al., 2003) . Specifically, Westphalen and Hemmings (2006) illustrated that isoflurane can enhance basal release of GABA and inhibit basal release of glutamate from isolated rat cortical nerve terminals, and intracellular calcium buffering can limit the isofluraneinduced inhibition of basal glutamate release. Hollmann et al. (2001) reported that clinically relevant concentrations of isoflurane, sevoflurane, or desflurane can reduce current associated with NR1/NR2A and NR1/NR2B expressed recombinantly in Xenopus oocytes with a reversible, concentration-dependent, and voltage-insensitive manner. Isoflurane has also been reported to block NMDA-stimulated currents in cultured hippocampus neurons (Yang and Zorumski, 1991) and to attenuate glutamatedependent intraneuronal translocation of Ca 2ϩ (Puil et al., 1990) . Recent studies showed that isoflurane can block NMDA receptor-mediated current , and NMDA receptor antagonist (ϩ)-5-methyl-10,11-dihydro-5H-dibenzo [a,d] cyclohepten-5,10-imine maleate (MK-801) can decrease the minimum alveolar concentration of isoflurane . In addition, isoflurane has been reported to attenuate LTP in hippocampus slices from mice, and GABA antagonist picrotoxin can inhibit the effects of isoflurane (Simon et al., 2001) . Collectively, these findings suggest that isoflurane may inhibit NMDA neurotransmission. However, other studies suggested that isoflurane does not inhibit NMDA transmission (Pearce et al., 1989) ; in fact, a recent study showed that isoflurane may actually increase NMDA receptor activity by enhancing phosphorylation at S896 of the NR1 subunit of NMDA receptor (Zhan et al., 2006) . We therefore postulate that isoflurane may affect NMDA neurotransmission with a concentration-and duration-dependent 2) . There is no significant difference in amounts of ␤-actin in control or NR1 siRNA-treated cells. B, Quantitation of the Western blots shows that NR1 siRNA treatment (black) reduces protein levels of NR1 compared with control siRNA treatment (white). A t test is used to compare difference between control siRNA and NR1 siRNA treatment in reducing NR1 protein levels (*p ϭ 0.0439). C, Treatment with control siRNA plus isoflurane (lanes 5 and 6) induces caspase-3 activation compared with control siRNA plus control condition (lanes 1 and 2). NR1 siRNA alone (lanes 3 and 4) does not induce caspase-3 activation. However, treatment with NR1 siRNA plus isoflurane (lanes 7 and 8) induces a lesser degree of caspase-3 activation compared with a treatment with control siRNA plus isoflurane (lanes 5 and 6). The Western blot, which shows the caspase-3 fragment (17 kDa) only, is the same Western blot with longer exposure time during the film development. D, Quantification of the Western blot shows that control condition plus NR1 siRNA treatment (gray) dose not induce caspase-3 activation compared with control condition plus control siRNA treatment (white). The treatment with isoflurane plus control siRNA (black) induces caspase-3 activation compared with control condition plus control siRNA treatment (white). NR1 siRNA treatment (lined) attenuates the isoflurane-induced (black) caspase-3 activation. Data are means Ϯ SD (n ϭ 3-6 for each experimental group). A t test is used to compare the difference. *p ϭ 0.041, difference between isoflurane and control condition on caspase-3 activation; # p ϭ 0.037, difference between control siRNA and NR1 siRNA on isoflurane-induced caspase-3 activation.
manner. With low concentration and short duration of treatment, isoflurane may inhibit NMDA neurotransmissionassociated calcium influx to produce neuroprotection effects (e.g., preconditioning). With high concentration and long duration of treatment, however, isoflurane may potentiate NMDA neurotransmission-associated calcium influx to trigger cell damage (e.g., apoptosis). Future studies will be necessary to assess the effects of different concentrations and durations of isoflurane treatments on NMDA neurotransmission and NMDA neurotransmission-associated calcium influx to further test this hypothesis.
It is also possible that isoflurane can induce apoptosis via non-NMDA neurotransmission-associated calcium influx. Indeed, El Beheiry et al. (2007) showed that reduction in exogenous calcium concentration and selective blockade of L-type calcium channel with nifedipine can reduce the isoflurane-induced suppression of evoked dendritic field EPSPs in hippocampus slides from old rats. These findings suggest that isoflurane can act on different types of calcium channels to affect cell functions. It will be interesting in future studies to test the effects of various calcium channel blockers, including nifedipine (L-type), -conotoxin GVIA (Ntype), and -conotoxin MVIIC (P/Qtype) (El Beheiry et al., 2007) , on isoflurane-induced apoptosis and A␤ generation.
Memantine, a newly FDA approved drug for AD treatment, is an uncompetitive (partial) antagonist of the NMDA receptor (for review, see Lipton, 2006) . Memantine has a low affinity for the NMDA receptor channel pore and thus has a fast off-rate compared with other NMDA receptor antagonists (e.g., MK-801). This character of memantine enables memantine to only enter the NMDA receptor channel when the channel is opened by an agonist. Therefore, memantine will not accumulate in the NMDA receptor channel and will not interfere with normal synaptic transmission associated with NMDA receptor (Lipton, 1993; Lipton and Rosenberg, 1994; Chen and Lipton, 1997 ) (for review, see Lipton, 2006) . Memantine, an NMDA receptor uncompetitive (partial) antagonist, is different from NMDA noncompetitive antagonists, including MK-801, ketamine, and phencyclidine, in clinical acceptance, because of the fact that memantine can preferentially block NMDA receptor-operated channels when they are excessively open while relatively sparing normal neurotransmission (for review, see Lipton, 2006) . Our current findings showing that NMDA receptors exist in H4-APP cells (Figs. 1 E, 4A) , and that the NMDA partial antagonist memantine can attenuate isoflurane-induced apoptotic cell damage in H4-APP cells and in naive mice, suggest that memantine may act on NMDA receptors to inhibit isofluraneinduced apoptotic cell damage. Moreover, these findings suggest that memantine may be used to pharmacologically intervene with isoflurane-induced apoptosis and subsequent neurotoxicity in patients, especially elderly and AD patients.
Previous studies have suggested that isoflurane can induce apoptosis by activating the ryanodine receptor in the ER to facilitate calcium release from ER to the cytoplasm (Wei et al., 2005) . IP 3 receptors and SERCA1 can also regulate cytosolic calcium levels (Berridge, 1993; Zhang et al., 2006) . Activation of IP 3 receptors can cause elevated cytosolic calcium levels, leading to cell death (Hanson et al., 2004; Lindholm et al., 2006) . RNAi knockdown of SERCA1 can inhibit calcium influx and calcium releaseactivated calcium channel activity. We therefore assessed the roles of the IP 3 receptor and SERCA1 in isoflurane-induced caspase-3 activation. Knockdown of IP 3 receptor and SERCA1 in H4-APP cells attenuated isoflurane-induced caspase-3 activation, suggesting that isoflurane can induce apoptosis by activating IP 3 receptor and/or SERCA1, facilitating calcium release from the ER to the cytoplasm.
Although isoflurane has been reported to induce caspase acti- Figure 5 . EDTA, low calcium, and BAPTA attenuate isoflurane-induced caspase-3 activation in H4-APP cells. A, Treatment with isoflurane plus low-calcium condition (lanes 3 and 4) yields a reduction in caspase-3 cleavage (activation) compared with isoflurane treatment alone (lanes 1 and 2) in H4-APP cells. Treatment with isoflurane plus low-calcium condition and EDTA (lanes 5 and 6) causes an even lesser degree of caspase-3 activation compared with either isoflurane treatment alone (lanes 1 and 2) or the treatment of isoflurane plus low-calcium condition (lanes 3 and 4). There is no significant difference in the amounts of ␤-actin in all of the above treatments in H4-APP cells. The Western blot, which shows the caspase-3 fragment (17 kDa) only, is the same Western blot with longer exposure time during the film development. B, Caspase-3 activation assessed by quantifying the ratio of caspase-3 fragment to FL-caspase-3 in the Western blots. The treatment with isoflurane and low-calcium condition (gray) induces a reduction in caspase-3 activation compared with isoflurane treatment alone (white). The treatment with isoflurane plus low-calcium condition and EDTA (black) triggers an even lesser degree of caspase-3 activation compared with either isoflurane treatment alone (white) or the treatment with isoflurane plus low-calcium condition (gray). C, Treatment with DMSO plus isoflurane (lanes 5 and 6) induces caspase-3 activation compared with DMSO plus control condition (lanes 1 and 2). BAPTA alone (lanes 3 and 4) does not induce caspase-3 activation. However, treatment with BAPTA plus isoflurane (lanes 7 and 8) induces a lesser degree of caspase-3 activation compared with a treatment with DMSO plus isoflurane (lanes 5 and 6). D, Quantification of the Western blot shows that control condition plus BAPTA treatment (gray) dose not induce caspase-3 activation compared with control condition plus DMSO treatment (white). The treatment with isoflurane plus DMSO (black) induces caspase-3 activation compared with control condition plus DMSO treatment (white). BAPTA treatment (lined) attenuates the isoflurane-induced (black) caspase-3 activation. Data are means Ϯ SD (n ϭ 3-6 for each experimental group). A t test is used to compare the difference. *p ϭ 0.046, difference between isoflurane plus low-calcium condition and isoflurane plus normal calcium condition; *p ϭ 0.015, difference between isoflurane plus normal calcium condition and isoflurane plus low-calcium condition and EDTA; # p ϭ 0.029, difference between isoflurane plus low-calcium condition and isoflurane plus low-calcium condition and EDTA; *p ϭ 0.0103, difference between isoflurane and control condition on caspase-3 activation; # p ϭ 0.045, difference between BAPTA and control treatment on isoflurane-induced caspase-3 activation.
vation and to cause apoptosis (Matsuoka et -Faberowski et al., 2001; de Klaver et al., 2002; Kawaguchi et al., 2004; Wise-Faberowski et al., 2004; Gray et al., 2005) . This difference could be attributable to the use of different cell lines (e.g., rat cardiac cells vs human neural cells) or differences in duration and concentration of isoflurane exposure (Xie et al., 2006a,b) . A transient and moderate elevation of cytosolic calcium levels after a lower concentration of isoflurane treatment for a short duration could provide cytoprotection via upregulating host preconditioning response Bickler and Fahlman, 2006; Zhan et al., 2006) . However, prolonged exposure to a high concentration of isoflurane may maintain IP 3 receptor in an open status, thereby elevating cytosolic calcium levels and ultimately leading to cell damage (Orrenius et al., 2003; Paschen and Mengesdorf, 2005) .
Our in vitro and limited in vivo studies as well as other findings suggest that isoflurane may affect AD neuropathogenesis; however, it is necessary to perform further determination of the in vivo relevance of these effects, including in vivo apoptosis (e.g., terminal deoxynucleotidyl transferase-mediated biotinylated UTP nick end labeling) studies, given that caspase activation alone may not represent apoptotic cell damage (McLaughlin et al., 2003) , before we can conclude that the inhalation anesthetic isoflurane promotes AD neuropathogenesis in humans.
In conclusion, we have shown that decreases in cytosolic calcium levels by reduction in extracellular and intracellular calcium levels, treatment with the NMDA antagonist memantine, or RNAi silencing of the IP 3 receptor, NR1, or SERCA1 can attenuate isoflurane-induced apoptosis. These findings suggest a therapeutic strategy for preventing potential isoflurane-associated neurotoxicity (and A␤ generation) based on reducing cytosolic calcium levels. Moreover, we found that this can be achieved pharmacologically by using memantine. In the future studies aimed at further defining the molecular mechanism by which isoflurane induces caspase activation and apoptosis, we will assess effects of isoflurane on cytosolic calcium levels and whether the isoflurane-induced caspase activation and apoptosis are dependent on cytosolic calcium levels. Given the aging of the population and growing numbers of patients with AD who require surgery and general anesthesia, more studies in elucidating the molecular mechanism by which isoflurane induces apoptosis and potentiates A␤ generation are warranted. Our current study indicating that isoflurane-induced apoptosis is dependent on cytosolic calcium levels will hopefully lead to the provision of safer anesthesia care, especially for AD and elderly patients. 1 and 4) . The treatment with control siRNA plus isoflurane (lane 1) induces caspase-3 activation compared with control siRNA plus control condition (lane 4). The treatment of IP 3 receptor siRNA plus control condition (lanes 5 and 6) does not induce caspase-3 activation compared with control siRNA plus control condition (lane 4). However, the treatment with IP 3 receptor siRNA plus isoflurane (lanes 2 and 3) yields a reduction in caspase-3 activation compared with the treatment with control siRNA plus isoflurane (lane 1). B, Quantitation of the Western blots shows that IP 3 receptor siRNA treatment (black) reduces the protein levels of IP 3 receptor compared with control siRNA treatment (white). A t test is used to compare the difference between control siRNA and IP 3 receptor siRNA treatment in reducing IP 3 receptor protein levels (*p ϭ 0.026). C, Control condition plus IP 3 siRNA treatment (gray) dose not induce caspase-3 activation compared with control condition plus control siRNA treatment (white). The treatment with either isoflurane plus control siRNA (black) or isoflurane plus IP 3 receptor siRNA (lined) causes caspase-3 activation compared with control condition plus control siRNA treatment (white). However, IP 3 receptor siRNA treatment (lined) attenuates the isoflurane-induced (black) caspase-3 activation. Data are means Ϯ SD (n ϭ 3-6 for each experimental group). A t test is used to compare the difference. **p ϭ 0.001, **p ϭ 0.008, the difference between isoflurane and control condition on caspase-3 activation; # p ϭ 0.035, the difference between control siRNA and IP 3 receptor siRNA on the isofluraneinduced caspase-3 activation. 2) . There is no significant difference in amounts of ␤-actin in control or SERCA1 siRNA-treated cells. B, Quantitation of the Western blots shows that SERCA1 siRNA treatment (black) reduces protein levels of SERCA1 compared with control siRNA treatment (white). A t test is used to compare the difference between control siRNA and SERCA1 siRNA treatment in reducing SERCA1 protein levels (*p ϭ 0.021). C, Treatment with control siRNA plus isoflurane (lanes 4 and 5) induces caspase-3 activation compared with control siRNA plus control condition (lane 1). SERCA1 siRNA alone (lanes 2 and 3) does not induce caspase-3 activation. However, treatment with SERCA1 siRNA plus isoflurane (lanes 6 and 7) induces a reduction in caspase-3 activation compared with the treatment with control siRNA plus isoflurane (lanes 4 and 5). The Western blot, which shows the caspase-3 fragment (17 kDa) only, is the same Western blot with longer exposure time during the film development. D, Quantification of the Western blot shows that control condition plus SERCA1 siRNA treatment (gray) dose not induce caspase-3 activation compared with control condition plus control siRNA treatment (white). Treatment with isoflurane plus control siRNA (black) induces caspase-3 activation compared with control condition plus control siRNA treatment (white). SERCA1 siRNA treatment (lined) attenuates the isoflurane-induced caspase-3 activation (black). Data are means Ϯ SD (n ϭ 4 for each experimental group). A t test is used to compare the difference. **p ϭ 0.001, difference between isoflurane and control condition on caspase-3 activation; # p ϭ 0.012, difference between control siRNA and SERCA1 siRNA on isoflurane-induced caspase-3 activation.
